Skip to main content
. 2017 May 23;8(34):56672–56683. doi: 10.18632/oncotarget.18074

Figure 5. Transfection of Wip1-shRNA impaired ICC-9810 and SSP25 cell tumor formation through MMP-2 in vivo.

Figure 5

Western blot/PCR revealed that shRNA-Wip1 remarkably decreased the levels of MMp-2 (A,B) Following down- regulation of Wip1 expression, ICC-9810 and SSP25 cells exhibited significantly diminished in vivo tumor formation ability compared with control cells (C, upper). Tumor size was measured every week. There was a significant reduction in relative tumor volume from shRNA-Wip1-treated animals when compared with untreated controls (C, down). The expression of Wip1/MMP-2 was positively correlated with subcutaneous tumor volume (D). *P<0.05.